Coraliotech

Coraliotech is a marine biotechnology company founded in 2018 and based in Monaco. Our activity is dedicated to the discovery, the production and the valorisation of promising marine molecules from coral organisms. Compared to many other species, the corals are still under-studied organisms and should represent a prodigious source of active natural substances with potential applications in the fields of human well-being and health. Unfortunately, since many decades, coral populations are faded and degraded by climate change, pollution and excessive human activities.

Related News

GREATER CFDNA RECOVERY MAY HELP ACCELERATE DEVELOPMENT OF CANCER LIQUID BIOPSY APPLICATIONS

PHASE Scientific | June 22, 2020

news image

PHASE Scientific, a high-growth biotechnology company that develops innovative sample preparation technologies, announced new findings at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II. The study presented by MD Anderson Cancer Center evaluates the efficacy of PHASE Scientific's liquid phase DNA isolation method (PHASIFY™) in improving cancer liquid biopsy sensitivity.Early-stage cancer diagnostics and cancer screening applications are limited ...

Read More

MEDTECH

TAVOTEK BIOTHERAPEUTICS ANNOUNCES COMPLETION OF ROUND B FINANCING WITH $35 MILLION

Tavotek | November 19, 2021

news image

Tavotek Biotherapeutics, a fast-growing biotech company, announces it has raised $35M in Round B financing. CS Capital, a leading private equity fund manager in China, led this finance round followed by Fontus Capital. This round of financing will be used to accelerate the Phase 1 clinical development of several antibody drugs to start in early 2022. The upcoming antibody drugs were developed by the company based on its TavoPrecise antibody platform for various immune-related disorders. In addit...

Read More

DIAGNOSTICS

PROVECTUS ALGAE EXPANDS INTO NEW LARGE-SCALE MICROALGAE BIOMANUFACTURING FACILITY

Provectus Algae | August 28, 2021

news image

Provectus Algae, an Australian biotechnology platform company specialising in the biomanufacturing of high-value compounds for a wide array of industries using microalgae, announced they will be expanding into an additional large-scale manufacturing facility. “Since closing our seed round last year, we have been in full swing growing the team, developing products and building capacity with our proprietary production system. We are now in a strong position as we push into thi...

Read More

MEDICAL

SLATE BIO ANNOUNCES THE LAUNCH WITH SEED FINANCING TO DEVELOP NEXT GENERATION IL-2 THERAPIES

Slate Bio | January 20, 2021

news image

Slate Bio, Inc., reports the closing of a $1.75 million venture financing. Epidarex Capital drove the speculation round with cooperation from the UVA Licensing and Ventures Group Seed Fund, Center for Innovative Technology's GAP BioLife Fund, VTC Seed Fund, PharmaDirections, Inc., the board and others. Record is a pre-clinical biotechnology organization creating outlook changing IL-2 mixes dependent on examination directed at the University of Virginia School of Medicine. IL233, Slate's ...

Read More
news image

GREATER CFDNA RECOVERY MAY HELP ACCELERATE DEVELOPMENT OF CANCER LIQUID BIOPSY APPLICATIONS

PHASE Scientific | June 22, 2020

PHASE Scientific, a high-growth biotechnology company that develops innovative sample preparation technologies, announced new findings at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II. The study presented by MD Anderson Cancer Center evaluates the efficacy of PHASE Scientific's liquid phase DNA isolation method (PHASIFY™) in improving cancer liquid biopsy sensitivity.Early-stage cancer diagnostics and cancer screening applications are limited ...

Read More
news image

MEDTECH

TAVOTEK BIOTHERAPEUTICS ANNOUNCES COMPLETION OF ROUND B FINANCING WITH $35 MILLION

Tavotek | November 19, 2021

Tavotek Biotherapeutics, a fast-growing biotech company, announces it has raised $35M in Round B financing. CS Capital, a leading private equity fund manager in China, led this finance round followed by Fontus Capital. This round of financing will be used to accelerate the Phase 1 clinical development of several antibody drugs to start in early 2022. The upcoming antibody drugs were developed by the company based on its TavoPrecise antibody platform for various immune-related disorders. In addit...

Read More
news image

DIAGNOSTICS

PROVECTUS ALGAE EXPANDS INTO NEW LARGE-SCALE MICROALGAE BIOMANUFACTURING FACILITY

Provectus Algae | August 28, 2021

Provectus Algae, an Australian biotechnology platform company specialising in the biomanufacturing of high-value compounds for a wide array of industries using microalgae, announced they will be expanding into an additional large-scale manufacturing facility. “Since closing our seed round last year, we have been in full swing growing the team, developing products and building capacity with our proprietary production system. We are now in a strong position as we push into thi...

Read More
news image

MEDICAL

SLATE BIO ANNOUNCES THE LAUNCH WITH SEED FINANCING TO DEVELOP NEXT GENERATION IL-2 THERAPIES

Slate Bio | January 20, 2021

Slate Bio, Inc., reports the closing of a $1.75 million venture financing. Epidarex Capital drove the speculation round with cooperation from the UVA Licensing and Ventures Group Seed Fund, Center for Innovative Technology's GAP BioLife Fund, VTC Seed Fund, PharmaDirections, Inc., the board and others. Record is a pre-clinical biotechnology organization creating outlook changing IL-2 mixes dependent on examination directed at the University of Virginia School of Medicine. IL233, Slate's ...

Read More